Your minor oversight. If they have 240 million they will invest in into either a bank account that pays interest or some kind of interest baring investment. The 180 million in notes due are 5 years away and in the mean time their interest will add to several millions more plus any drug they may come up with between now and 5 years from now.
They have plenty of cash for the next several years...and if they can fix the common cold drug to become approve they will be fixed for life. There is always a chance VPHM can partner with another company on future new drugs..
Minor oversight, I'm sure! What about their 180 million in notes due in 2007. That leaves 60 million now, and burning how fast! Anyway, using your math now divide 60 million by 22.7 m shares = less then $3.00 per share! Getting close, should be there in 3 or 4 more days!
Shorties Beware: Volume is drying up and I only see 110 million in debt and 240 in cash. What death bullet am I missing? Update: I am now in a full position at 3.95. It will be fun to watch it double over the next six months (In fact shorties, remember this post, because I'm throwing it in your faces in six months) Gooooooooo VPHM!!!!!!!!
On the conference call this was specifically asked and the answer is no. These notes are not callable.
VPHM has approximately 2 years more of life. After that who knows.
The cold drug is important but all the other stuff is important too. I always thought the RSV drug was actually more important because it involves a critical care issue. If it is effective, side effects not huge, it will be very valuable.
Picovir was always a shoot the moon drug and I thought it would have huge sales because doctors would prescribe - I did not think they would have great pricing power because many people would opt for antibiotics - cheap, or otc remedies - if too expensive.
RSV and other drugs will have pricing power, i.e. margins.
Do not cound Picovir out either on use for children or senior citizens - neither of which have a pregnancy problem.